EBiSC presents a new offering of iPSC-derived neurons
- Photo Info
- Download
A new EBiSC iPSC-derived neuronal cell product simplifies neuroscience research
The possibility to generate an unlimited amount of mature and functionally active neurons from human-induced pluripotent stem cells (iPSCs) has the potential to radically accelerate neuroscience research. However, differentiation protocols can be lengthy, expensive, and often produce inconsistencies in terms of yield and functionality. The European Bank for induced Pluripotent Stem Cells (EBiSC) is happy to announce a new iPSC derived neuronal cell product - EBiSC-NEUR1 which can be used directly from thaw for downstream applications.
“Making pre-differentiated neurons from the healthy BIONi010-C-13 lines, available via the EBiSC catalogue as a standard offering is a step forward for iPSC researchers worldwide,” explains Dr. Christian Clausen, CSO of Bioneer A/S, the RTO responsible for generating the original iPSC line and developing the differentiation protocol. “Issues with reproducibility and inconsistencies in differentiation are a real stumbling block for those not familiar with how to generate and handle iPSC-neurons. Now EBiSC has removed this challenge by making the cells plus a User protocol available for a non-profit transfer fee, to all researchers.”
EBiSC-NEUR1 cells are early neurons derived using a doxycycline-inducible NGN2 expression system within a healthy male iPSC line. The transcription-factor based differentiation approach accelerates generation of mature neurons while reducing cell culture variability. EBiSC-NEUR1 neurons can be thawed directly onto either mouse or human astrocytes for co-culture, showing robust viability and recovery, consistent neuronal morphology, phenotype, and functionality.
EBiSC-NEUR1 cultures exert a great homogeneity with low batch-to-batch variability providing an ideal starting point for diverse co-culture approaches as well as large-scale assays and high-throughput drug screenings. EBiSC-NEUR1 can be accessed via the non-profit EBiSC catalogue ( https://ebisc.org/EBISC-NEUR1).
The EBiSC catalogue is in constant expansion and will continue collecting iPSC lines associated with various disorders as well as offering iPSC related services and providing future additional cell products representing different cell types and lineages.
The European Bank for induced pluripotent Stem Cells (EBiSC) is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient, and consistent, high-quality tools for new medicines development. Learn more at ebisc.org and search the EBiSC catalogue at cells.ebisc.org. Follow the EBiSC journey on Twitter @EBiSC_cells and EBiSC’s LinkedIn https://www.linkedin.com/company/EBiSC and subscribe here to receive detailed EBiSC news by mail.
Bioneer A/S is a trusted strategic R&D partner to biotech and pharmaceutical companies, founded in 1982. With dedicated and highly skilled employees, state-of-the-art laboratory facilities, and a history of nearly 40 years of operation, Bioneer delivers innovative solutions to the Life Science industry, as a Danish government-approved Research and Technology Organization. Bioneer operates as an extended R&D team and trusted strategic partner for researchers, bringing added value with their unique know-how and advanced technologies. Find out more at bioneer.dk/ and stay in touch at www.linkedin.com/company/bioneer/.
Related publications:
Generation of two gene edited iPSC-lines carrying a DOX-inducible NGN2 expression cassette with and without GFP in the AAVS1 locus. Stem Cell Research, 52 (2021)
Development of a fully human assay combining NGN2-inducible neurons co-cultured with iPSC-derived astrocytes amenable for electrophysiological studies. Stem Cell Research, 54 (2021)
Scalable expansion of iPSC and their derivatives across multiple lineages. Reproductive Toxicology 112 (2022)
EBiSC on social media:
Twitter @EBiSC_cells
LinkedIn www.linkedin.com/company/EBiSC
EBiSC Newsroom
PRESS CONTACTS
Tanja Oster, EBiSC2 Project Office at ebisc2@eurtd.com | Contact@EBiSC.org
EBiSC has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI2 JU) in the context of in the context of the projects EBiSC (grant agreement No 115582) and the EBiSC2 (grant agreement No 821362). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. More about the IHI JU at www.ihi.europa.eu
ARTTIC Innovation GmbH has been advising research and innovation projects for more than 33 years. As project management and communication partner, we make sure that our projects run successfully and that project results and events are disseminated in the best possible way. ARTTIC is a subsidiary of the PNO Group, one of the largest consultancies for publicly funded projects in research and development. For more information, please visit www.arttic-innovation.de.